← Leaderboards
David Allen Ralph
Navidea Biopharmaceuticals, Inc.
$2,331,001
Attributed
$3,193,501
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2015–19$2M$1.5M$1M$500K$0
'15
'16
'17
'18
'19
Funding mix
By agency
NIH$3,193,501 · 4
By mechanism
R44$2,968,501 · 3
R41$225,000 · 1
Top collaborators
- Michael Blue1 shared
- Suzanne Elizabeth Lapi1 shared
Most similar at Navidea Biopharmaceuticals, Inc.
Same institution · by research overlap
- Frederick Oliver Cope$8,156,978
- Michael Blue$750,000
Others in their field
Top investigators on “Evaluation”
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- David Heimbrook · Leidos Biomedical Research, Inc.$564,050,020
- Lawrence Corey · Fred Hutchinson Cancer Center$559,122,174
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$489,869,793
- Jeffrey P Krischer · University Of South Florida$466,087,841
- Judith S. Currier · University Of California Los Angeles$403,175,569
Research focus
EvaluationLifeMacrophageSentinel Lymph NodeSpecificityCancer SurgeryMannose ReceptorTumorDesignSmall Business Innovation Research GrantPharmaceutical PreparationsCellsSolid NeoplasmRadiopharmaceuticalsFda ApprovedLymphaticBiological ProductsAnimalsLymph NodesSafetyBaseClinical ResearchDiagnosticDetection
Grant awards (4)
Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques$225,000
R41 · FY2019 · HL
CD206 Targeted Therapy for Kaposi Sarcoma and Tumor Associated Macrophages$601,993
R44 · FY2018 · CA · contact PI
Receptor Mediated SPECT Imaging Of Kaposi Sarcoma With 99mTc-Tilmanocept$866,508
R44 · FY2017 · CA · contact PI
99mTc-Tilmanocept for Sentinel Lymph Node Biopsy in Cervical Cancer Surgeries$1,500,000
R44 · FY2015 · CA · contact PI